NCT04731038

Combination Therapy for First Line Treatment of Advanced Cervical Cancer

Combination of Paclitaxel, Cisplatin\Carboplatin With Toripalimab and Anlotinib for First Line Treatment of Advanced Cervical Cancer

• Status: Unknown
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 20 (estimated)
• Sponsor: Ruijin Hospital · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This is a single center phase 1 trail to observe safety and efficacy of Paclitaxel plus Cisplatin\\Carboplatin, PD-L1 antibody Toripalimab and Anlotinib as first-line regimen to treat the patient with metastatic 、persistent or recurrent disease after radical surgery、radical platinum-based concurrent chemoradiotherapy or both (Stage IA-IVA).

Detailed description

Advanced cervical cancer patients with metastatic, persistent or recurrent disease after radical surgery、radical platinum-based concurrent chemoradiotherapy or both will be treated by Paclitaxel plus Cisplatin\\Carboplatin, PD-L1 antibody Toripalimab and Anlotinib.

Conditions

• Advanced Cervical Cancer

Interventions

Type	Name	Description
DRUG	Anlotinib, Toripalimab, Paclitaxel, Cisplatin/ Carboplatin	This is a single-arm study with all patients receiving these four drugs.

Timeline

• Start date: 2021-08-01
• Primary completion: 2022-07-01
• Completion: 2024-07-01
• First posted: 2021-01-29
• Last updated: 2021-09-17

Locations

1 site across 1 country: China